Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Inventory (2021 - 2023)

DiaMedica Therapeutics filings provide 3 years of Inventory readings, the most recent being $317000.0 for Q4 2023.

  • Quarterly Inventory rose 654.76% to $317000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $317000.0 through Dec 2023, up 654.76% year-over-year, with the annual reading at $317000.0 for FY2023, 654.76% up from the prior year.
  • Inventory hit $317000.0 in Q4 2023 for DiaMedica Therapeutics, down from $715000.0 in the prior quarter.
  • Across five years, Inventory topped out at $715000.0 in Q3 2023 and bottomed at $42000.0 in Q4 2022.
  • Average Inventory over 3 years is $223000.0, with a median of $102500.0 recorded in 2021.
  • The largest annual shift saw Inventory plummeted 62.83% in 2022 before it skyrocketed 654.76% in 2023.
  • DiaMedica Therapeutics' Inventory stood at $113000.0 in 2021, then plummeted by 62.83% to $42000.0 in 2022, then skyrocketed by 654.76% to $317000.0 in 2023.
  • Per Business Quant, the three most recent readings for DMAC's Inventory are $317000.0 (Q4 2023), $715000.0 (Q3 2023), and $59000.0 (Q2 2023).